Perioperative supplementation with a fruit and vegetable juice powder concentrate and postsurgical morbidity: a double-blind, randomised, placebo controlled clinical trial.
Surgical removal of lower third molars (wisdom teeth) is one of the most common 86 surgical procedures. It is associated with marked postoperative morbidity as a 87 consequence of surgical trauma, including pain, swelling and reduced mouth opening 88 (trismus) (1, 2). Whilst it is recognised that there is significant inter-individual variability 89 in postoperative morbidity, patient-level determinants remain poorly understood. 90
Reactive Oxygen Species (ROS) b released by inflammatory cells, in particular 91 neutrophils, play a key role in wound healing, with normal ROS levels facilitating 92 healing, and excess ROS creating oxidative stress. Oxidative stress activates major redox-93 regulated pro-inflammatory signalling cascades via the redox-sensitive gene transcription 94 factor Nuclear Factor kappa-B (NFkB), and thus the redox status of healing tissues and 95 their constituent cells impacts upon wound healing dynamics (3, 4) . A wide variety of 96 antioxidant micronutrients (AM) a are implicated in regulating the redox environment 97 during wound healing. Excess ROS are removed by various antioxidant systems working 98 in concert via redox cycling reactions, such as vitamins E, C and the non-radical 99 tripeptide, Reduced Glutathione (GSH) d , the terminal stage of which results in the 100 oxidation of GSH to its oxidized counterpart GSSG e (5). GSH however, must be 101 synthesised by cells, a process that requires the activation of the redox-regulated gene 102 transcription factor Nuclear Factor E2 (Erythroid 2)-Related Factor 2 (NRF2) f (6, 7). 103
Whole food nutrition rather than individual vitamin supplementation is therefore 104 generally recommended in order to maintain AM in homeostatic balance and preserve 105 GSH, which is a powerful regulator of cellular redox state and thus of key transcriptional 106 events. In acute models of rodent wound healing, tissue levels of GSH, ascorbate and 107 vitamin E show a sustained decrease of 60-70% after wounding (8). Furthermore, tissue 108 levels of AM are considerably reduced in the wounds of aged rats relative to young rats M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 7 (9), and in immunosuppressed rats compared with immunocompetent animals (10). Thus, 110 impaired healing appears to be associated with reduced AM tissue levels known to affect 111 key redox-regulated signalling pathways, such as NRF2 and NFkB. 112
Given the role of ROS in wound healing and control of infection, there is a surprising 113 paucity of data on the effect of AM intake and wound healing, including the incidence of 114 post-surgical complications/morbidity. Therefore, here we report a double-blind, placebo-115 controlled, randomised clinical trial to ascertain the efficacy of pre-operative 116 supplementation with encapsulated fruit and vegetable juice powder concentrate to reduce 117 postoperative morbidity and improve QoL following lower third molar surgery. 118
119

Materials and Methods 120
Study design and participants 121
The FAVOURITE study was a randomised, double-blind, placebo-controlled two-arm 122 Patients were asked to take two capsules, twice daily with food (= four supplements per 165 day) for 10 weeks prior to their surgical intervention. Following wisdom tooth surgery, 166
participants were asked to continue taking the study medication for the first postoperative 167
week. 168
Capsule counts were performed on the day of surgery and at the final study visit, when all 169 remaining capsules were returned to the study centre. 
Statistical analyses 207
Primary endpoint and sample size 208
The primary endpoint was the between group difference in oral health-related QoL over 209 the first postoperative week assessed with the PoSSe scale. The study required a 210 minimum of 170 patients (n=85 per group) in order to achieve 90% power to detect a 211 standardised effect size of 0.5 at a significance level of α=0.05, which would generally be 212 considered a clinically meaningful difference in QoL between groups (12). Subjects lost 213 to follow-up were replaced until the target sample size for the primary endpoint was 214 reached. 215 216
Secondary endpoints 217
Assessment of the following secondary endpoints was performed: 218
• Specific QoL domains (PoSSe subscales), 219
• Trismus on postoperative day 2 and day 7, i.e., the difference between the pre-220 operative interincisal distance on the day of surgery and the interincisal distance 221 two days and seven days following surgery, respectively, 222
• Mean pain score from postoperative days one to six, 223
• The proportion of patients that reported pain of 50mm or higher on day 2 and day 224 6, 225
• The proportion of patients experiencing an absolute increase of 20mm in pain 226 score on any day between postoperative day 4 and day 6, compared to the previous 227 day (a surrogate for alveolar osteitis/wound infection), 228
• The between-group difference in total consumption of analgesics during the first 229 post-operative week, 230
• Adverse Events (AEs) l . 231
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Statistical analysis was performed according to a pre-specified analysis plan (see online 234 supplement for details). Briefly, analyses were done according to the Intention-To-Treat 235 (ITT) o principle, which included all randomised patients who received the supplements 236 and returned for at least one follow-up appointment. Summary statistics were calculated 237 as appropriate. For comparisons between groups for primary and secondary endpoints we 238 calculated effect estimates, 95% confidence intervals and p-values for using appropriate 239 multiple regression models. In addition to unadjusted estimates, we calculated estimates all randomised patients were overall well balanced between the two treatment arms 258 (Table 1) . 259
260
ITT population 261
Of the 238 randomized patients, 19 patients allocated to F&V and 26 patients allocated to 262 placebo did not return for surgery. Therefore, surgery was performed in 193 participants. 263
A further ten patients (active n=3, placebo n=7) did not return for any follow-up 264 appointments. Hence, 183 patients had data available for at least one endpoint (ITT 265 population) ( Figure 1 ). Detailed descriptions of patients lost to follow-up and missing 266 data can be found in the Online Supplemental Material. Briefly, current smokers were less 267 likely to attend for surgery, and patients with poor oral hygiene and less extensive surgery 268
were less likely to attend for follow-up after surgery (Supplemental Table 1 On average, patients took more than 80% of the assigned capsules. There were no 281 statistically significant differences between active and placebo groups in terms of 282 
Secondary endpoints 300
Comparing active to placebo groups, the analysis of separate PoSSe domains shows 301 significantly lower impact for pain in unadjusted analyses, and significantly lower 302 impacts for pain, eating and sickness in analyses adjusted for baseline characteristics. 303
Following adjustments for surgical characteristics, none of the differences between 304 subscale impacts were statistically significant (Table 3) . Trismus (limitation of mouth 305 opening) on postoperative day 2 was lower in the active intervention compared to placebo 306 group by -3.1mm (95% CI: -6.1 to -0.1, p=0.042). Adjustment for baseline characteristics M A N U S C R I P T
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15 resulted in -3.7mm (95% CI: -6.6, 0.7, p=0.016). However, additional adjustment for 308 surgical factors resulted in an attenuated difference in trismus between groups (-2.7mm, 309 95% CI -5.6 to 0.2, p=0.069) (Table 3) . One week following surgery, the estimate of a 310 difference in trismus between active and placebo decreased to less than 1.5mm and 311 showed no statistical significance for any analysis. 312
The mean pain score for postoperative days 1 to 6 also revealed a statistically significant 313 difference between groups in all analyses, with a higher mean pain score by a mean of 314 8.5mm for the control group compared to the active group when adjusting for both 315 baseline and surgical factors (95% CI -15.5 to -1.6, p=0.017). The conclusion was the 316 same after imputation. 317
There was a 46% lower risk of VAS score over 50% on follow-up day 2 in the active 318 group after adjusting for baseline and surgical covariates with a 95% CI 0.32 to 0.89, 319 which was statistically significant at the 5% significance level (p=0.015). 320
Other secondary outcomes were not statistically significantly different at the 5% 321 significance level between treatment groups (Table 3) . 322 323
Micronutrient levels 324
The levels of vitamin C, α-Tocopherol, α-Carotene, and β-Carotene were statistically 325 significantly higher in the F&V group compared to placebo, following 10 weeks of 326 supplementation and having adjusted for their respective baseline levels (Table 4) . For 327 active compared to placebo between baseline and surgery, the mean difference in vitamin 328 C was 23.6µmol/L (95% CI 17.1 to 30.1, p<0.001), the mean difference for β-Carotene 329 was 1.13µmol/L (95% CI 0.88 to 1.38, p<0.001), the mean difference for α-Tocopherol 330 was 2.86µmol/L (95% CI 1.69 to 4.05, p<0.001), and the mean difference in α-Carotene 331 was 0.02µmol/L (95% CI 0.00 to 0.03, p=0.045). For these AMs, the treatment effect M A N U S C R I P T
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estimates were also statistically significant at day 2 and day 7 for active compared to 333 placebo after adjusting for the baseline levels. There were no statistically significant 334 differences between treatment groups for the other micronutrients. Estimated serum 335
SMAC was significantly higher in the active compared to the placebo group at the time of 336 surgery. 337 338
Adverse events 339
In total 14 AEs, which were classified as having a "possible" or "probable" relationship 340 with the intervention, were recorded. The vast majority of these (n=11) were 341 gastrointestinal (GI) q upset, mainly nausea and bloating. Other possible AEs were 342 "itchiness" (n=2) and "tiredness" (n=1). All of the patients with GI upset stopped taking 343 the supplements, as did one patient with itchiness (50%) and the one patient with reported 344 tiredness. Overall, 57% of AEs were reported in the placebo group (GI upset n=5 (45%), 345 itchiness n=2 (100%), tiredness n=1 (100%)). These results need to be cautiously interpreted in light of the limitations of this study. 365
Firstly, the supplements evaluated in the present study are made from a wide variety of 366 different fruit and vegetables and are enriched with carotenoids and vitamins. It is 367 therefore unclear which specific constituents or combination of constituents would be 368 responsible for any observed effect. However, evidence suggests that the beneficial 369 effects of higher fruit and vegetable consumption on inflammatory diseases are 370 attributable to the additive and synergistic interactions of the plethora of phytochemicals 371 present in whole foods by targeting multiple signal transduction pathways (21), and these 372 mechanisms could be underpinnig the effects observed in the present study. The 373 supplements evaluated here have been shown to contain a substantial amount of different 374 (poly)phenolic compounds, demonstrating that the capsules preserve these compounds as 375 they occur in the large variety of source plants used in their manufacture (22). 376
Alternatively, the observed effect may be attributable to a few or a single specific 377 constituent. Serum concentrations of α-tocopherol, β-carotene and vitamin C increased 378 significantly over 10 weeks of supplement intake in the active group, and marked 379 differences between groups in the plasma concentrations of these micronutrients were 380 evident at the time of surgery, resulting in higher estimated small molecule antioxidant 381 capacity in serum (Table 4) (28-30). In the present study, the strongest effects were observed for the secondary pain 389 endpoints, with patients in the verum group being almost half as likely to experience 390 moderate to severe pain 2 days after surgery than patients in the placebo group, and 391 reduced pain levels could directly or indirectly explain the effects on other endpoints. 392
Secondly, the observed p-values for the primary endpoint, as well as several secondary 393 endpoints hover around the 5% significance level, depending on if and what baseline and 394 surgical characteristics are included in the statistical models. In the absence of anchor-395 based estimates of a minimally important difference in QoL following third molar 396 surgery, the sample size was set to achieve 90% power to detect a standardised effect size 397 of 0.5 (12). However, research on other patient reported outcomes suggests that 398 standardised effect sizes of 0.2-0.3 would represent small but important, i.e., clinically 399 significant differences (31). The effect sizes observed in this trial for QoL (including the 400 eating, sickness and pain subscales) and the secondary endpoints of pain and trismus were 401 in that range or slightly larger. However, our study lacked power to detect differences 402 smaller than 0.5 and the possibility that the observed differences are due to chance must 403 be acknowledged. 404
Loss to follow-up before surgery was relatively high at 19%, but was unlikely to be 405 related to the intervention and cannot have been related to the study outcomes as these 406 patients did not receive surgery. Current smoking was the only baseline characteristic that M A N U S C R I P T
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was significantly associated with patients not attending for surgery, possibly a marker of 408 lower compliance, which has also been reported in the context of observational research 409 (32-34). Our secondary analyses adjusted for surgical factors deemed important for 410 surgical morbidity, including markers of surgical complexity/severity of trauma (bone 411 removal, tooth sectioning, duration of surgery) and pre-operative chlorhexidine rinse (35). 412
While these are variables collected after randomisation, the difficulty of surgery/surgical 413 trauma or decision to use pre-operative chlorhexidine rinse cannot have reasonably been 414 affected by group assignment in this double-blind trial, and these statistical adjustments 415 allow appreciation of the effect of chance differences between groups. As can be expected 416 for a moderately sized trial, some imbalances were observed at baseline, including a 417 moderately higher vitamin C concentration in the active group. In a post-hoc sensitivity 418 analysis, adjustment for baseline vitamin C concentrations yielded similar estimates 419 (results not shown). 420
Finally, patients in the present study received supplements for a relatively long period of 421 10 weeks preoperatively. Nutritional supplement formulations such as the one evaluated 422 in this study are usually taken long-term, and in the absence of short-term 423 pharmacokinetic data we were confident that steady state would be achieved by 10 weeks 424 (36). However, such preoperative supplementation for 10 weeks would be difficult or 425 impossible to implement in many clinical scenarios, and short-term supplementation 426 should therefore be evaluated in future studies. Notwithstanding these uncertainties and 
